APA (7th ed.) Citation

Nishida, S., Ishikawa, T., Kokura, S., Egawa, S., Koido, S., Yasuda, H., . . . Sugiyama, H. (2016). Randomized phase II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic ductal adenocarcinoma (PDAC): Clinical efficacy and immune response. Journal of Clinical Oncology, 34(15_suppl), 3085. https://doi.org/10.1200/jco.2016.34.15_suppl.3085

Chicago Style (17th ed.) Citation

Nishida, Sumiyuki, et al. "Randomized Phase II Study of WT1 Peptide Vaccine Plus Gemcitabine for Advanced Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Efficacy and Immune Response." Journal of Clinical Oncology 34, no. 15_suppl (2016): 3085. https://doi.org/10.1200/jco.2016.34.15_suppl.3085.

MLA (9th ed.) Citation

Nishida, Sumiyuki, et al. "Randomized Phase II Study of WT1 Peptide Vaccine Plus Gemcitabine for Advanced Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Efficacy and Immune Response." Journal of Clinical Oncology, vol. 34, no. 15_suppl, 2016, p. 3085, https://doi.org/10.1200/jco.2016.34.15_suppl.3085.